Protecting the kidneys and cardiovascular system in type 2 diabetes

Abstract

Get full access to this article

View all access options for this article.

References

Parving HH , Hovind P. , Rossing K. et al. Evolving strategies for renoprotection: diabetic nephropathy . Curr Opin Nephrol Hypertens 2001;10:515-22.

Ritz E. , Rychlik I. , Locatelli F. et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999 ; 34:795-808.

United States Renal Data System : USRDS 1997 Annual Data Report. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD 1998.

Foley RN , Parfrey PS , Sarnak MJ Clinical epidemiology of cardiovascular disease in chronic renal disease . Am J Kidney Dis 1998;32(suppl 3):S112-S19.

Stack AG , Bloembergen WE A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001;38:992-1000.

United States Renal Data System : Extracts from the USRDS 1999 Annual Data Report. Am J Kidney Disease 1999;34(suppl 1):S1-S176.

Haffner SM , Lehto S. , Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N Engl J Med 1998;339:229-34.

Stephenson JM , Kenny S. , Stevens LK et al. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995;12:149-55.

Foley RN , Parfrey PS , Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-92.

10.

Tarnow L. , Rossing P. , Gall MA et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17:1247-51.

11.

Hansson L. , Zanchetti A. , Carruthers SG et al. and the HOT Study group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.

12.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998;317:703-13.

13.

Ramsey L. , Williams B. , Johnston G. et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999;13:569-92.

14.

Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.

15.

Shoji T. , Emoto M. , Kawagishi T. et al. Atherogenic lipoprotein changes in diabetic nephropathy. Atherosclerosis 2001;156:425-33.

16.

Stamler J. , Vaccaro O. , Neaton JD et al. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.

17.

Pyorala K. , Pedersen TR , Kjekshus J. et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.

18.

Goldberg RB , Mellies MJ , Sacks FM et al. for The Care Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-19.

19.

Diabetes Atherosclerosis Interventions Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.

20.

Krolewski AS , Warram JH , Christlieb AR Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy . Kidney Int 1994;45(suppl 45):S125-31.

21.

Department of Health. National Service Framework for Coronary Artery Disease: Modern Standards and Service Models, HMSO, London, 2000.

22.

The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.

23.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

24.

Chachou A. , Randoux C. , Millart H. et al. Influence of in vivo hemoglobin carbamylation on HbA1c measurements by various methods. Clin Chem Lab Med 2000 ;38:321-6.

25.

O'Riordan E. , Foley RN Effects of anaemia on cardiovascular status . Nephrol Dial Transplant 2000;15(suppl 3):19-22.

26.

Antiplatelet Trialists ' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patient. BMJ 1994;308:81-106.

27.

Gottlieb SS , McCarter RJ , Vogel RA Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction . N Engl J Med 1998;339:489-97.